High-density lipoprotein subclass profile and mortality in patients with coronary artery disease: Results from the GENES study;Relation entre la répartition des sous-classes de HDL et la mortalité chez des patients coronariens : résultats de l’étude GENES

Archives of Cardiovascular Diseases

Volumn 109, Issue 11, 2016, Pages 607-617

  Elbaz, Meyer ^a,b,c   Faccini, Julien ^a,b   Bongard, Vanina ^b,d   Ingueneau, Cécile ^a,b   Taraszkiewicz, Dorotea ^b,c,d   Perret, Bertrand ^a,c   Ferrières, Jean ^b,c,d   Ruidavets, Jean Bernard ^b,c   Vindis, Cécile ^a,b  

^a University Hospital of Toulouse   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d Faculté de Médecine Centre Hospitalo universitaire   (France)

Author keywords

Coronary artery disease; High density lipoprotein; High density lipoprotein subclasses; Mortality

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE; BIOLOGICAL MARKER;

ADULT; AGE; ANKLE BRACHIAL INDEX; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; FEMALE; FOLLOW UP; GENSINI SCORE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HEMATOLOGY ANALYZER; HUMAN; KAPLAN MEIER METHOD; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY RATE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTICLE SIZE; PHENOTYPE; PHYSICAL ACTIVITY; PROPORTIONAL HAZARDS MODEL; TOBACCO CONSUMPTION; WAIST CIRCUMFERENCE; AGED; BLOOD; CORONARY ARTERY DISEASE; EPIDEMIOLOGY; FRANCE; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; TRENDS;

AGED; BIOMARKERS; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE;

EID: 84996607157     PISSN: 18752136     EISSN: 18752128     Source Type: Journal    
DOI: 10.1016/j.acvd.2016.04.007     Document Type: Article

References (29)

1. [1] Di Angelantonio, E., Sarwar, N., Perry, P., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302 (2009), 1993–2000.
2. [2] Castelli, W.P., Garrison, R.J., Wilson, P.W., Abbott, R.D., Kalousdian, S., Kannel, W.B., Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256 (1986), 2835–2838.
3. [3] Pirillo, A., Norata, G.D., Catapano, A.L., High-density lipoprotein subfractions—what the clinicians need to know. Cardiology 124 (2013), 116–125.
4. [4] Barter, P., Gotto, A.M., LaRosa, J.C., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357 (2007), 1301–1310.
5. [5] Voight, B.F., Peloso, G.M., Orho-Melander, M., et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380 (2012), 572–580.
6. [6] Barter, P.J., Caulfield, M., Eriksson, M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007), 2109–2122.
7. [7] Boden, W.E., Probstfield, J.L., Anderson, T., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365 (2011), 2255–2267.
8. [8] Mackey, R.H., Greenland, P., Goff, D.C. Jr., Lloyd-Jones, D., Sibley, C.T., Mora, S., High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol 60 (2012), 508–516.
9. [9] Martin, S.S., Khokhar, A.A., May, H.T., et al. HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the Lipoprotein Investigators Collaborative. Eur Heart J 36 (2015), 22–30.
10. [10] Oravec, S., Dostal, E., Dukat, A., Gavornik, P., Kucera, M., Gruber, K., HDL subfractions analysis: a new laboratory diagnostic assay for patients with cardiovascular diseases and dyslipoproteinemia. Neuro Endocrinol Lett 32 (2011), 502–509.
11. [11] Xu, R.X., Li, S., Li, X.L., et al. High-density lipoprotein subfractions in relation with the severity of coronary artery disease: a Gensini score assessment. J Clin Lipidol 9 (2015), 26–34.
12. [12] Durackova, Z., Muchova, J., Andrezalova, L., Oravec, S., Nagyova, Z., Garaiova, I., Paraoxonase 1 and HDL subfractions in hypercholesterolemic children and adolescents. Free Radic Biol Med, 75(Suppl. 1), 2014, S29.
13. [13] Hascoet, S., Elbaz, M., Bongard, V., et al. Adiponectin and long-term mortality in coronary artery disease participants and controls. Arterioscler Thromb Vasc Biol 33 (2013), e19–e29.
14. [14] Bouisset, F., Bongard, V., Ruidavets, J.B., et al. Prognostic usefulness of clinical and subclinical peripheral arterial disease in men with stable coronary heart disease. Am J Cardiol 110 (2012), 197–202.
15. [15] Gensini, G.G., A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol, 51, 1983, 606.
16. [16] Califf, R.M., Phillips, H.R. 3rd, Hindman, M.C., et al. Prognostic value of a coronary artery jeopardy score. J Am Coll Cardiol 5 (1985), 1055–1063.
17. [17] Ducimetiere, P., Guize, L., Marciniak, A., Milon, H., Richard, J., Rufat, P., Arteriographically documented coronary artery disease and alcohol consumption in French men. The CORALI Study. Eur Heart J 14 (1993), 727–733.
18. [18] Smith, S.C. Jr., Blair, S.N., Bonow, R.O., et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 104 (2001), 1577–1579.
19. [19] MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002), 7–22.
20. [20] Cannon, C.P., Blazing, M.A., Giugliano, R.P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 (2015), 2387–2397.
21. [21] Rizzo, M., Otvos, J., Nikolic, D., Montalto, G., Toth, P.P., Banach, M., Subfractions and subpopulations of HDL: an update. Curr Med Chem 21 (2014), 2881–2891.
22. [22] Superko, H.R., Pendyala, L., Williams, P.T., Momary, K.M., King, S.B. 3rd, Garrett, B.C., High-density lipoprotein subclasses and their relationship to cardiovascular disease. J Clin Lipidol 6 (2012), 496–523.
23. [23] Mora, S., Otvos, J.D., Rifai, N., Rosenson, R.S., Buring, J.E., Ridker, P.M., Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 119 (2009), 931–939.
24. [24] Alagona, C., Soro, A., Ylitalo, K., Salonen, R., Salonen, J.T., Taskinen, M.R., A low high density lipoprotein (HDL) level is associated with carotid artery intima-media thickness in asymptomatic members of low HDL families. Atherosclerosis 165 (2002), 309–316.
25. [25] McQueen, M.J., Hawken, S., Wang, X., et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 372 (2008), 224–233.
26. [26] Nissen, S.E., Tsunoda, T., Tuzcu, E.M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. Jama 290 (2003), 2292–2300.
27. [27] Tardif, J.C., Ballantyne, C.M., Barter, P., et al. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J 35 (2014), 3277–3286.
28. [28] de Souza, J.A., Vindis, C., Negre-Salvayre, A., et al. Small, dense HDL 3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipoprotein A-I. J Cell Mol Med 14 (2010), 608–620.
29. [29] de Souza, J.A., Vindis, C., Hansel, B., et al. Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity. Atherosclerosis 197 (2008), 84–94.